Oral Cancer Chemoprevention--The End of EPOC, the Beginning of an Epoch of Molecular Selection

Affiliations

¹ Division of Hematology/Oncology, Department of Internal Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
² Department of Otolaryngology, University of California San Francisco, San Francisco.

Editorial

Julie E Bauman et al. JAMA Oncol. 2016 Feb.

. 2016 Feb;2(2):178-9.

doi: 10.1001/jamaoncol.2015.4637.

¹ Division of Hematology/Oncology, Department of Internal Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
² Department of Otolaryngology, University of California San Francisco, San Francisco.

No abstract available

Comment on

Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial.
William WN Jr, Papadimitrakopoulou V, Lee JJ, Mao L, Cohen EE, Lin HY, Gillenwater AM, Martin JW, Lingen MW, Boyle JO, Shin DM, Vigneswaran N, Shinn N, Heymach JV, Wistuba II, Tang X, Kim ES, Saintigny P, Blair EA, Meiller T, Gutkind JS, Myers J, El-Naggar A, Lippman SM. William WN Jr, et al. JAMA Oncol. 2016 Feb;2(2):209-16. doi: 10.1001/jamaoncol.2015.4364. JAMA Oncol. 2016. PMID: 26540028 Free PMC article. Clinical Trial.